Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Centrexion Therapeutics Corporation    CNTX

CENTREXION THERAPEUTICS CORPORATION

(CNTX)
 SummaryQuotesNewsCompanyFinancials 
Financials (USD)
Sales 2017 - - -
Net income 2017 -24,6 M - -
Net cash position 2017 58,7 M - -
P/E ratio 2017 -
Yield 2017 -
Sales 2018 - - -
Net income 2018 -39,0 M - -
Net cash position 2018 23,8 M - -
P/E ratio 2018 -
Yield 2018 -
Capitalization - - -
EV / Sales 2017 -
EV / Sales 2018 -
Nbr of Employees 24
Free-Float -
More Financials
Company
Centrexion Therapeutics Corp is a late clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing therapies to address the unmet medical need for the treatment of chronic pain. Its product candidate pipeline includes CNTX-4957, CNTX-0290, CNTX-6970, CNTX-2022 and CNTX-6016. Its product candidates are designed to treat pain conditions of multiple etiologies... 
Sector
Pharmaceuticals
Calendar
-
More about the company
All news about CENTREXION THERAPEUTICS CORPORATION
2019Centrexion Therapeutics Announces Issuance of U.S. Composition of Matter Pate..
GL
2019Centrexion Therapeutics Announces CNTX-4975 Data Presentations at the 2019 Am..
GL
2019Centrexion Therapeutics Announces Completion of Patient Enrollment in VICTORY..
GL
2019CORRECTION - Centrexion Therapeutics
GL
2019Centrexion Therapeutics Announces CNTX-4975, CNTX-0290 and CNTX-6970 Data Pre..
GL
2019Centrexion Therapeutics to Present New Positive Clinical Trial Results on Str..
GL
2019Centrexion Therapeutics to Announce CNTX-4975 Trial Results at the European L..
GL
2019Centrexion Therapeutics Announces Completion of Patient Enrollment in Pivotal..
GL
2019Centrexion Therapeutics Announces CNTX-4975 Data Presentations at the 2019 Br..
GL
2019Centrexion Therapeutics Announces Publication of Phase 2 Efficacy Data on CNT..
GL
2019Centrexion Therapeutics Announces CNTX-4975 Preclinical and Clinical Data Pre..
GL
2018Centrexion Therapeutics Announces Completion of Patient Enrollment in Pivotal..
GL
More news
News in other languages on CENTREXION THERAPEUTICS CORPORATION

- No features available -

More news
Chart CENTREXION THERAPEUTICS CORPORATION
Duration : Period :
Centrexion Therapeutics Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers
NameTitle
Jeffrey B. Kindler Chief Executive Officer & Director
James N. Campbell President, Director, & Chief Scientific Officer
Sol J. Barer Chairman
Peter Hanson Chief Development Operations Officer & EVP
Nick Harvey CFO, Treasurer, Principal Accounting Officer & EVP
Sector and Competitors